Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Details : HQP1351 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 07, 2020
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Details : HQP1351 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 15, 2019
Details : HQP1351 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 20, 2019
Details : HQP1351 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 20, 2019
Details : HQP1351 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 20, 2019
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Details : HQP1351 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gastrointestinal Stromal Tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 20, 2018